Loading
Melanoma oncologist who led the tebentafusp programme in the United States and defined targeted therapy for rare melanoma subtypes.
Richard Carvajal co-led the tebentafusp development programme including the pivotal IMCgp100-202 trial in metastatic uveal melanoma and the early trials of MEK inhibition in uveal melanoma, and led studies of imatinib in KIT-mutant melanoma. He directs medical oncology at Northwell and continues to focus on rare melanoma subtypes.
Shares gp100 (PMEL), IMCgp100-202, Tebentafusp, Uveal melanoma and the tag uveal-melanoma.
Shares IMCgp100-202, Tebentafusp, Uveal melanoma, Melanoma.
Shares Tebentafusp, T-cell engagers (bispecific), Melanoma.
Shares Tebentafusp, Uveal melanoma, Melanoma.
Shares Tebentafusp, Uveal melanoma, T-cell engagers (bispecific), Melanoma.
Shares Uveal melanoma, Melanoma.
Shares Uveal melanoma, Melanoma.